Brought to you by 
Takeda signs RNAi deal with Alnylam
03 Jun 2021
Executive Summary
In a new five-year deal, Alnylam has granted Takeda Pharmaceutical worldwide, nonexclusive rights to an RNAi-based therapeutics technology in the areas of metabolic diseases and cancer, with an option to include additional indications at a later date.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Royalty or Profit Split Information
- Product or Technology Swap
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com